Malene Schou Nielsson

Malene Schou Nielsson

Auto-generated profile, based on publicly available information

Malene Schou Nielsson

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; Department of Anaesthesia and Intensive Care Medicine, Aalborg University Hospital, Aalborg, Denmark

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2013 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Closed access
PDF file
MNM. S. Nielsson
M. S. Nielsson
CCC. F. Christiansen
C. F. Christiansen
MJMartin Johansen
Martin Johansen
BRB. S. Rasmussen
B. S. Rasmussen
ETE. Tønnesen
E. Tønnesen
MNM. Nørgaard
M. Nørgaard

1 August 2012 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
MNMalene Schou Nielsson
Malene Schou Nielsson
RERune Erichsen
Rune Erichsen
TFTrine Frøslev
Trine Frøslev
ATAliki Taylor
Aliki Taylor
JAJohn Acquavella
John Acquavella
VEVera Ehrenstein
Vera Ehrenstein
Background: The purpose of this study was to estimate the positive predictive value (PPV) of the coding for bisphosphonate treatment in selected cancer patients from the Danish National Patient Registry (DNPR). Methods: Through the DNPR, we identified all patients with recorded cancer of the breast, prostate, lung, kidney, and with multiple myeloma. We restricted the study sample to patients with bisphosphonate treatment recorded during an admission to Aalborg Hospital, Denmark, from 2005 through 2009. We retrieved and reviewed medical records of these patients from the initial cancer diagnosis onwards to confirm or rule out bisphosphonate therapy. We calculated the PPV of the treatment coding as the proportion of patients with confirmed bisphosphonate treatment. Results: We retrieved and reviewed the medical records of 60 cancer patients with treatment codes corresponding to bisphosphonate therapy. Recorded code corresponded to treatment administered intravenously for 59 of 60 patients, corresponding to a PPV of 98.3% (95% confidence interval 92.5–99.8). In the remaining patient, bisphosphonate treatment was also confirmed but was an orally administered bisphosphonate; thus, the treatment for any bisphosphonate regardless of administration was confirmed for all 60 patients (PPV of 100%, 95% confidence interval 95.9–100.0). Conclusion: The PPV of bisphosphonate treatment coding among cancer patients in the DNPR is very high and the recorded treatment nearly always corresponds to intravenous administration.

1 January 2010 in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
Verified
Journal Article
Open access
PDF file
MNMalene S Nielsson
Malene S Nielsson
JMJacob Madsen
Jacob Madsen
PLPer H Lambert
Per H Lambert